
Amphastar Pharmaceuticals AMPH
€ 25.76
0.6%
Amphastar Pharmaceuticals Langfristige Verbindlichkeiten | AMPH
Langfristige Verbindlichkeiten Jährlich Amphastar Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 682 M | 671 M | 648 M | 118 M | 122 M | 70.3 M | 69.4 M | 42.4 M | 50.1 M | 37.9 M | 34.7 M | 44.9 M | 21.8 M | 24 M | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 682 M | 21.8 M | 188 M |
Langfristige Verbindlichkeiten Vierteljährlich Amphastar Pharmaceuticals
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 716 M | 712 M | 710 M | 682 M | 684 M | 681 M | 676 M | 671 M | 658 M | 641 M | 647 M | 648 M | 692 M | 538 M | 119 M | 118 M | 119 M | 121 M | 122 M | 122 M | 124 M | 74 M | 67.7 M | 70.3 M | 66 M | 64.3 M | 66.1 M | 69.4 M | 65.4 M | 68 M | 52.5 M | 42.4 M | 42.8 M | 43.5 M | 50.1 M | 50.1 M | 49.7 M | 47 M | 37.2 M | 37.9 M | 39.5 M | 35.5 M | 33.5 M | 34.7 M | 40.6 M | 44.3 M | 45.1 M | 44.9 M | 54.9 M | 53.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quartalsentwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 716 M | 33.5 M | 234 M |
Langfristige Verbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
UroGen Pharma Ltd.
URGN
|
260 M | $ 28.91 | -8.89 % | $ 1.39 B | ||
|
Catalyst Biosciences
CBIO
|
981 K | $ 13.01 | 0.74 % | $ 1.16 B | ||
|
ARCA biopharma
ABIO
|
1.31 M | - | 1052.0 % | $ 415 M | ||
|
ADiTx Therapeutics
ADTX
|
343 K | - | - | $ 374 | ||
|
Aeterna Zentaris
AEZS
|
14 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
3.42 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
3.86 M | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
3.49 M | - | 1.93 % | $ 17.4 M | ||
|
Aileron Therapeutics
ALRN
|
1.06 M | - | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
33.2 M | - | 4.14 % | $ 49.1 M | ||
|
Apellis Pharmaceuticals
APLS
|
382 M | - | - | $ 5.18 B | ||
|
Athira Pharma
ATHA
|
16.9 M | - | - | $ 269 M | ||
|
AVROBIO
AVRO
|
43 K | - | 1083.1 % | $ 745 M | ||
|
AstraZeneca PLC
AZN
|
34.7 B | - | - | $ 96.9 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
618 K | - | -2.5 % | $ 5.88 M | ||
|
BeiGene, Ltd.
BGNE
|
2 B | - | 0.49 % | $ 251 B | ||
|
EyePoint Pharmaceuticals
EYPT
|
20.9 M | $ 0.23 | -12.11 % | $ 16.8 K | ||
|
Bio-Path Holdings
BPTH
|
434 K | - | - | $ 100 K | ||
|
Cara Therapeutics
CARA
|
85 K | - | -3.03 % | $ 260 M | ||
|
ChromaDex Corporation
CDXC
|
9.95 M | - | -0.88 % | $ 598 M | ||
|
Caladrius Biosciences
CLBS
|
72 K | - | -16.75 % | $ 25.8 M | ||
|
Cyclacel Pharmaceuticals
CYCC
|
2 K | - | -5.98 % | $ 34.1 M | ||
|
Diffusion Pharmaceuticals
DFFN
|
480 K | - | 11.68 % | $ 8.97 M | ||
|
Eloxx Pharmaceuticals
ELOX
|
5.24 M | - | -5.68 % | $ 8.28 M | ||
|
Enochian Biosciences
ENOB
|
56.2 K | - | - | $ 40.5 M | ||
|
Esperion Therapeutics
ESPR
|
355 M | - | - | $ 661 M | ||
|
Evofem Biosciences
EVFM
|
4.89 M | - | 7.55 % | $ 38.1 M | ||
|
Eyenovia
EYEN
|
8 M | - | 49.81 % | $ 13.2 M | ||
|
FibroGen
FGEN
|
85.9 M | - | - | $ 889 M | ||
|
Homology Medicines
FIXX
|
8.42 M | - | 0.77 % | $ 53.4 M | ||
|
Amicus Therapeutics
FOLD
|
245 M | - | - | $ 4.47 B | ||
|
Frequency Therapeutics
FREQ
|
50.1 M | - | - | $ 528 M | ||
|
Galecto
GLTO
|
81 K | - | - | $ 762 M | ||
|
GlycoMimetics
GLYC
|
1.21 M | - | 9357.83 % | $ 1.01 B | ||
|
Graybug Vision
GRAY
|
16.4 M | - | -11.23 % | $ 9.65 M | ||
|
Galera Therapeutics
GRTX
|
152 M | - | -32.59 % | $ 7.61 M | ||
|
Happiness Biotech Group Limited
HAPP
|
1.38 M | - | 1.35 % | $ 17.8 M | ||
|
Novavax
NVAX
|
844 M | $ 7.47 | -3.24 % | $ 1.21 B | ||
|
Hepion Pharmaceuticals
HEPA
|
103 K | - | -18.79 % | $ 39.3 K | ||
|
Hoth Therapeutics
HOTH
|
2.71 K | - | - | $ 18.8 M | ||
|
IMARA
IMRA
|
67 K | - | 15.96 % | $ 663 M | ||
|
KalVista Pharmaceuticals
KALV
|
110 M | - | - | $ 1.45 B | ||
|
KemPharm
KMPH
|
90.8 M | - | -0.34 % | $ 200 M | ||
|
Kezar Life Sciences
KZR
|
5.46 M | - | - | $ 53.3 M | ||
|
Lixte Biotechnology Holdings
LIXT
|
439 K | - | - | $ 63.4 M | ||
|
Magenta Therapeutics
MGTA
|
6.79 M | - | -7.74 % | $ 41.6 M | ||
|
NovaBay Pharmaceuticals
NBY
|
639 M | - | - | $ 11.3 M | ||
|
NeuroBo Pharmaceuticals
NRBO
|
142 K | - | 0.43 % | $ 12 M | ||
|
OncoCyte Corporation
OCX
|
45.1 M | - | 17.22 % | $ 355 K | ||
|
Onconova Therapeutics
ONTX
|
100 K | - | -0.47 % | $ 21 M |